Formulation: A solid
Formal Name: (S)-N6-(propyl-2,2,3,3,3-d5)-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine, dihydrochloride
Purity: ≥99% deuterated forms (d1-d5)
Formula Markup: C10H12D5N3S • 2HCl
Formula Weight: 289,3
Shelf life (days): 1460
CAS Number: 1217601-58-5
Notes: (S)-Pramipexole-d5 is intended for use as an internal standard for the quantification of (S)-pramipexole (Item No. 11981) by GC- or LC-MS. (S)-Pramipexole is a dopamine D2S, D2L, D3, and D4 receptor agonist (EC50s = 426.58, 338.84, 2.24, and 128.82 nM, respectively, in a [35S]GTPγS binding assay).{21786} It is also a partial agonist of α2A-adrenergic receptors (α2A-ARs; EC50 = 3,548.13 nM). (S)-Pramipexole is selective for dopamine D2-4 receptors (Kis = 954.99, 1,698.24, 12.59, 128.82 nM for D2S, D2L, D3, and D4 receptors, respectively, in a radioligand binding assay) over D1 and D5 receptors (Kis = >10,000 nM for both).{21785} It prevents MPTP-induced decreases in the number of dopaminergic neurons in the substantia nigra pars compacta in common marmosets when administered at a dose of 60 μg/kg per day before, during, and after administration of MPTP.{53929} Formulations containing (S)-pramipexole have been used in the treatment of Parkinson's disease and restless legs syndrome.
English
Deutsch
